MIRA INFORM REPORT

 

 

Report Date :

11.10.2013

 

IDENTIFICATION DETAILS

 

Name :

GREEN CROSS CORP

 

 

Registered Office :

Green Cross Co. 107, Ihyeon-Ro 30beon-Gil, Giheung-Gu Yongin, 446770  Korea

 

 

Country :

South Korea

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

01.11.1969

 

 

Legal Form :

Public Parent

 

 

Line of Business :

Subject is engaged in the manufacture and sale of pharmaceutical products.

 

 

No. of Employees :

1,496

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

South Korea

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

SOUTH KOREA - ECONOMIC OVERVIEW

 

South Korea over the past four decades has demonstrated incredible growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion dollar club of world economies, and is currently the world's 12th largest economy. Initially, a system of close government and business ties, including directed credit and import restrictions, made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. Korea''s export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade Agreement was ratified by both governments in 2011 and went into effect in March 2012. Throughout 2012 the economy experienced sluggish growth because of market slowdowns in the United States, China, and the Eurozone. The incoming administration in 2013, following the December 2012 presidential election, is likely to face the challenges of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy''s long term challenges include a rapidly aging population, inflexible labor market, and heavy reliance on exports - which comprise half of GDP.

 

Source : CIA

 


Company name and address

 

GREEN CROSS CORP             

 

Green Cross Co.

107, Ihyeon-Ro 30beon-Gil, Giheung-Gu

Yongin, 446770

Korea, Republic of

 

 

Tel:

82-31-2609300

Fax:

82-31-2609413

 

www.greencross.com

 

Employees:

1,496

Company Type:

Public Parent

Corporate Family:

3 Companies

Traded:

Korea Stock Exchange:

006280

Incorporation Date:

01-Nov-1969

Auditor:

KPMG LLP

Financials in:

USD (In Millions)

Fiscal Year End:

31-Dec-2012

Reporting Currency:

South Korean Won

Annual Sales:

720.4  1

Net Income:

47.6

Total Assets:

895.0  2

Market Value:

1,498.5

 

(27-Sep-2013)

                                         

 

Business Description          

 

 

Green Cross Corporation is a Korea-based company engaged in the manufacture and sale of pharmaceutical products. The Company provides five categories of products: blood derivatives, which are plasma fractions used to treat immune deficiency diseases, albumin loss and blood coagulation; vaccines, including hepatitis B vaccines and epidemic hemorrhagic fever vaccines and others; diagnostic reagents such as rapid test kits and others; prescription drugs, which consist of antibiotics, digestive system remedies, circulatory system remedies, rheumatism remedies, respiratory system remedies and others; over-the-counter (OTC) drugs, including cataplasms, digestives, vitamins, anodynes and remedies used in atopic dermatitis and others, as well as infusion products, painkiller and medical equipment. For the six months ended 30 June 2013, Green Cross Corp revenues increased 2% to W385.38B. Net income increased 28% to W34.88B. Revenues reflect South Korea segment increase of 4% to W397.68B, Foreign segment increase of 2% to W5.58B. Net income benefited from Foreign segment income increase from W75M to W281M, Consolidation Adjustment segment income increase of 10% to W972M.

 

 

 

Industry

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2120 - Manufacture of pharmaceutical preparations

NAICS 2012:

325414 - Biological Product (except Diagnostic) Manufacturing

UK SIC 2007:

2120 - Manufacture of pharmaceutical preparations

US SIC 1987:

2836 - Biological Products, Except Diagnostic Substances

 

 

 

 

Key Executives

 

Name

Title

Sang Hun Cho

Assistant Managing Director

Ji Hun Han

Internal Auditor

Hul Il Sup

Chief Executive Officer

Soon-tae Cho

Co-President

Chang Hui Lee

Managing Director

 

 

Significant Developments   

 

 

Topic

#*

Most Recent Headline

Date

Business Deals

3

Green Cross Corp Signs Contract with Thai Red Cross Society

4-Jan-2013

Equity Financing / Related

3

Green Cross Corp Announces Amendments to Rights Issue

28-May-2013

Equity Investments

1

Ildong Pharmaceutical Co., Ltd. Announces Changes in Shareholding Structure

10-Dec-2012

Debt Financing / Related

1

Green Cross Corp Announces Amendments to Rights Issue

27-May-2013

Share Repurchases

1

Green Cross Corp Announces Share Repurchase

27-Aug-2013

 

 

* number of significant developments within the last 12 months

 

 

News

 

Title

Date

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013 - New Market Study Published
UK PRWire (704 Words)

9-Oct-2013

New Market Study, "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013", Has Been Published
SBWire (756 Words)

9-Oct-2013

PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF LONICERA JAPONICA FOR PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE
European Patents (118 Words)

8-Oct-2013

Trials begin on liver cancer drug
Hospital Pharmacy Europe (191 Words)

8-Oct-2013

USPTO ISSUES TRADEMARK: STRATEGEE RESEARCH + SOFTWARE + CONSULTING
U.S. Fed News (203 Words)

8-Oct-2013

Greg Tassell And Gary Branch
Cranbrook People (158 Words)

6-Oct-2013

 

 

 

Financial Summary

 

As of 30-Jun-2013

Key Ratios

Company

Industry

Current Ratio (MRQ)

2.72

2.09

Quick Ratio (MRQ)

1.49

1.48

Debt to Equity (MRQ)

0.05

0.43

Sales 5 Year Growth

12.91

4.13

Net Profit Margin (TTM) %

7.76

17.06

Return on Assets (TTM) %

6.57

9.59

Return on Equity (TTM) %

8.63

18.98

 

 

Stock Snapshot

 

Traded: Korea Stock Exchange: 006280

 

As of 27-Sep-2013

   Financials in: KRW

Recent Price

138,000.00

 

EPS

4,985.38

52 Week High

165,274.78

 

Price/Sales

1.99

52 Week Low

115,500.00

 

Dividend Rate

1,160.33

Avg. Volume (mil)

0.03

 

Price/Earnings

21.71

Market Value (mil)

1,612,742.00

 

Price/Book

2.22

 

 

 

Beta

0.65

 

Price % Change

Rel S&P 500%

4 Week

9.96%

5.29%

13 Week

12.65%

4.33%

52 Week

-12.02%

-13.03%

Year to Date

6.41%

5.63%

 

1 - Profit & Loss Item Exchange Rate: USD 1 = KRW 1126.849
2 - Balance Sheet Item Exchange Rate: USD 1 = KRW 1066.4

 

 

Corporate Overview

 

Location
Green Cross Co.
107, Ihyeon-Ro 30beon-Gil, Giheung-Gu
Yongin, 446770
Korea, Republic of

 

Tel:

82-31-2609300

Fax:

82-31-2609413

 

www.greencross.com

Quote Symbol - Exchange

006280 - Korea Stock Exchange

Sales KRW(mil):

811,774.3

Assets KRW(mil):

954,379.5

Employees:

1,496

Fiscal Year End:

31-Dec-2012

 

Industry:

Biotechnology and Drugs

Incorporation Date:

01-Nov-1969

Company Type:

Public Parent

Quoted Status:

Quoted

 

Co-Chief Executive Officer, Director:

Yil Seop Huh

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

3491

-

Professional and Scientific Goods Wholesaling

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

4649

-

Wholesale of other household goods

 

NACE Rev 2 Codes:

2120

-

Manufacture of pharmaceutical preparations

4646

-

Wholesale of pharmaceutical goods

2110

-

Manufacture of basic pharmaceutical products

 

NAICS 2012 Codes:

325414

-

Biological Product (except Diagnostic) Manufacturing

325412

-

Pharmaceutical Preparation Manufacturing

325411

-

Medicinal and Botanical Manufacturing

423450

-

Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

 

US SIC 1987:

2836

-

Biological Products, Except Diagnostic Substances

5047

-

Medical, Dental, and Hospital Equipment and Supplies

2833

-

Medicinal Chemicals and Botanical Products

2834

-

Pharmaceutical Preparations

 

UK SIC 2007:

2120

-

Manufacture of pharmaceutical preparations

4646

-

Wholesale of pharmaceutical goods

2110

-

Manufacture of basic pharmaceutical products

 

 

Business Description

 

Green Cross Corporation is a Korea-based company engaged in the manufacture and sale of pharmaceutical products. The Company provides five categories of products: blood derivatives, which are plasma fractions used to treat immune deficiency diseases, albumin loss and blood coagulation; vaccines, including hepatitis B vaccines and epidemic hemorrhagic fever vaccines and others; diagnostic reagents such as rapid test kits and others; prescription drugs, which consist of antibiotics, digestive system remedies, circulatory system remedies, rheumatism remedies, respiratory system remedies and others; over-the-counter (OTC) drugs, including cataplasms, digestives, vitamins, anodynes and remedies used in atopic dermatitis and others, as well as infusion products, painkiller and medical equipment. For the six months ended 30 June 2013, Green Cross Corp revenues increased 2% to W385.38B. Net income increased 28% to W34.88B. Revenues reflect South Korea segment increase of 4% to W397.68B, Foreign segment increase of 2% to W5.58B. Net income benefited from Foreign segment income increase from W75M to W281M, Consolidation Adjustment segment income increase of 10% to W972M.

*

 

More Business Descriptions

Manufacture of pharmaceuticals and finished medicaments

Pharmaceutical Product Mfr & Whslr

Green Cross Corporation (Green Cross), formerly Green Cross Sang-A, is a pharmaceutical company that researches, develops, produces and markets of a range of prescription and over the counter pharmaceuticals. Its prescription drugs comprise 14 products covering various therapeutic areas and its over-the-counter (OTC) drugs consist of seven products. The key categories in which the company develops its products are blood derivatives, which are plasma fractions for the treatment of immune deficiency diseases, blood coagulation and albumin loss; vaccines, which include hepatitis B vaccines, epidemic hemorrhagic fever vaccines, chicken pox vaccines and others; diagnostic reagents such as hepatitis B rapid test reagents, blood-grouping reagents and others; OTC which consist of vitamins, digestive system remedies, diabetes treatments, circulatory system remedies and others. The company distributes its products through a network of distribution channels. Green Cross is headquartered in Yongin, Korea. The company focuses on the development of biologics, which offers a huge potential market. This is reflected from its product pipeline being developed from natural sources. The company also concentrates on collaboration agreements for expanding the supply of its current product line and innovating new drug candidates through gaining of research expertise as well as platform technologies to gain market share.The company reported revenues of (Won) KRW 811,774.31 million during the fiscal year ended December 2012, an increase of 5.71% over 2011. The operating profit of the company was KRW 74,355.68 million during the fiscal year 2012, a decrease of 12.92% from 2011. The net profit of the company was KRW 53,643.05 million during the fiscal year 2012, a decrease of 3.11% from 2011.

Pharmaceutical and Medicine Manufacturing

 

 

Financial Data

 

Financials in:

KRW(mil)

 

Revenue:

811,774.3

Net Income:

53,643.1

Assets:

954,379.5

Long Term Debt:

8,129.2

 

Total Liabilities:

282,550.2

 

Working Capital:

30.0

 

 

 

Date of Financial Data:

31-Dec-2012

 

1 Year Growth

5.7%

-3.1%

10.9%

 

 

Market Data

 

Quote Symbol:

006280

Exchange:

Korea Stock Exchange

Currency:

KRW

Stock Price:

138,000.0

Stock Price Date:

09-27-2013

52 Week Price Change %:

-12.0

Market Value (mil):

1,612,742,016.0

 

SEDOL:

6771708

ISIN:

KR7006280002

 

Equity and Dept Distribution:

'03-'06, financials are consolidated. '98-'02, '07-'09, financials are non-consolidated. 10/2004, Company name changed from Green Cross Sang-A Corporation. 10/10, rights issue (F: 1.015391). 04/13 Rights Issue (F:1.017065)

 

 

Shareholders

 

Major Shareholders

Green Cross Holdings Corporation (52%)

 

 

Key Corporate Relationships

 

 

Auditor:

KPMG LLP

 

Auditor:

KPMG LLP

 

 

Corporate Family

 

Corporate Structure News:

Total Corporate Family Members: 3

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

 

Employees

Green Cross Corp

Parent

Yongin

Korea, Republic of

Pharmaceutical Manufacturing

720.4

1,496

Green Cross Engineering Maintenance Co., Ltd.

Subsidiary

Yongin-Gun

Korea, Republic of

Specialty Construction Trade Contractors

34.7

94

Sanga Pharmaceutical Co., Ltd.

Subsidiary

Yongin-Gun

Korea, Republic of

Pharmaceutical Manufacturing

 

 

 

 

 

Competitors Report

 

CompanyName

Location

Employees

Ownership

Estechpharma Co., Ltd.

Hwaseong, Korea, Republic of

149

Public

Genexine Inc

Seongnam, Korea, Republic of

77

Public

Hutchison Medipharma Limited

Zhangjiang, China

 

Private

Seoul Pharma Co., Ltd.

Siheung, Korea, Republic of

223

Public

ViroMed Co Ltd

Seoul, Korea, Republic of

52

Public

 

 

Executives Report

 

Board of Directors

 

Name

Title

Function

Il-sup Huh

 

Chairman

Chairman

Hul Il Sup

 

Chief Executive Officer

Chairman

Age: 58

Sang Hun Cho

 

Assistant Managing Director

Director/Board Member

 

Age: 58

Yil Seop Huh

 

Co-Chief Executive Officer, Director

Director/Board Member

 

Biography:

Huh Yil Seop si Co-Chief Executive Officer and Director of Green Cross Corporation. Currently Huh also serves as Vice Chairman of the Board and Chief Executive Officer of Green Cross Holdings Corporation. Huh holds a Bachelor's degree in Commerce from Seoul National University, Korea, a Masters of Business Administration from Indiana University, and a Doctorate's degree in Business Administration from University of Houston, the United States.

Age: 58

Education:

Indiana University, MBA
University of Houston, DS (Business Administration)
Seoul National University, B (Commerce)

Eun Cheol Huh

 

Vice President, Director

Director/Board Member

 

Biography:

Huh Eun Cheol has been serving as Vice President and Director of Green Cross Corporation since March 12, 2010. Prior to the current position, Huh served as Managing Director at the Company. Huh holds a Doctorate's degree in Food Engineering from Cornell University, the United States.

Age: 41

Education:

Cornell University, PHD

Yeong Ho Kim

 

Vice President, Director

Director/Board Member

 

Biography:

Kim Yeong Ho has been serving as Vice President and Director of Green Cross Corporation since March 15, 2013. Kim also serves as Chief Executive Officer of GCAM. Kim was Managing Director of the Company. Kim holds a Bachelor's degree in Chemistry from Kyung Hee University, Korea.

Age: 57

Education:

Kyung Hee University, B (Chemistry)

Byeong Geon Lee

 

Co-President, Co-Chief Executive Officer, Director

Director/Board Member

 

Biography:

Lee Byeong Geon has been serving as Co-President, Co-Chief Executive Officer and Director of Green Cross Corporation since March 12, 2010. Previously, Lee was Vice President of the Company. Lee holds a Bachelor's degree in Chemical Engineering from Seoul National University, Korea.

Age: 56

Education:

Rice University, PHD
Seoul National University, B (Chemical Engineering)

Chang Hui Lee

 

Managing Director

Director/Board Member

Reuters 

 

Age: 49

Education:

Korea University, B

Myeong Jae Lee

 

Non-Executive Independent Director

Director/Board Member

 

Biography:

Lee Myeong Jae is Non-Executive Independent Director of Green Cross Corporation. Lee was a Lawyer in Bae, Kim & Lee, a domestic law firm. Lee holds Bachelor of Law from Seoul National University, Korea.

Age: 70

Education:

Seoul National University, LLB

Seong Tae Yoon

 

Non-Executive Independent Director

Director/Board Member

 

Biography:

Yoon Seong Tae has been serving as Non-Executive Independent Director of Green Cross Corporation since March 17, 2006. Yoon is currently Professor in Health Science College of GACHON UNIVERSITY of MEDICINE and SCIENCE. Yoon holds a Bachelor of Law from Seoul National University, Korea, and a Doctorate's degree in Health Science from Yonsei University, Korea.

Age: 70

Education:

Yonsei University, PHD (Health Science)
Seoul National University, LLB

 

Executives

 

Name

Title

Function

 

Sang Hun Cho

 

Assistant Managing Director

Chief Executive Officer

 

Age: 58

Yil Seop Huh

 

Co-Chief Executive Officer, Director

Chief Executive Officer

 

 

Biography:

Huh Yil Seop si Co-Chief Executive Officer and Director of Green Cross Corporation. Currently Huh also serves as Vice Chairman of the Board and Chief Executive Officer of Green Cross Holdings Corporation. Huh holds a Bachelor's degree in Commerce from Seoul National University, Korea, a Masters of Business Administration from Indiana University, and a Doctorate's degree in Business Administration from University of Houston, the United States.

Age: 58

Education:

Indiana University, MBA
University of Houston, DS (Business Administration)
Seoul National University, B (Commerce)

Byeong Geon Lee

 

Co-President, Co-Chief Executive Officer, Director

Chief Executive Officer

 

 

Biography:

Lee Byeong Geon has been serving as Co-President, Co-Chief Executive Officer and Director of Green Cross Corporation since March 12, 2010. Previously, Lee was Vice President of the Company. Lee holds a Bachelor's degree in Chemical Engineering from Seoul National University, Korea.

Age: 56

Education:

Rice University, PHD
Seoul National University, B (Chemical Engineering)

Hul Il Sup

 

Chief Executive Officer

Chief Executive Officer

 

 

Age: 58

Soon-tae Cho

 

Co-President

President

 

 

Age: 58

Rhee Byeong Geon

 

President

President

 

 

Age: 56

Byung-Geon Rhee

 

Co-President

President

 

 

Pyeong Ju Jang

 

Assistant Managing Director

Managing Director

 

 

Age: 50

Mun Ho Jung

 

Assistant Managing Director

Managing Director

 

 

Age: 54

Education:

Chung-Ang University, B

Su Hyeon Jung

 

Managing Director

Managing Director

 

 

Age: 56

Education:

Yonsei University, B

Gyeong Jo Kim

 

Assistant Managing Director

Managing Director

 

 

Age: 54

Yeong Pil Kim

 

Managing Director

Managing Director

 

 

Age: 54

Education:

Korea University, M

Byeong Hwa Kim

 

Assistant Managing Director

Managing Director

 

 

Age: 52

Education:

Kyungpook National University, B

Seon Wuk Lee

 

Assistant Managing Director

Managing Director

 

 

Age: 48

Education:

Chung-Ang University, B

Yin Jae Lee

 

Assistant Managing Director

Managing Director

 

 

Age: 50

Education:

Chung-Ang University, MD

Chang Hui Lee

 

Managing Director

Managing Director

 

 

Age: 49

Education:

Korea University, B

Bok Su Park

 

Managing Director

Managing Director

 

 

Age: 57

Education:

Chosun University, B

Dae Wu Park

 

Managing Director

Managing Director

 

 

Age: 54

Education:

Keimyung University, B

Ji Hun Han

 

Internal Auditor

Accounting Executive

 

 

Biography:

Han Ji Hun has been serving as Internal Auditor of Green Cross Corporation since March 15, 2013. Previously Han served as Independent Director of the Company, Chief Executive Officer of a Korea-based Company and Vice President in Berna Biotech Korea. Corp. Han holds a Master's degree in International Business Management from Hankook University of Foreign Studies, Korea.

Age: 58

Education:

Hankook University of Foreign Studies, M (International Business Management)

Jong Ho Noh

 

Internal Auditor

Accounting Executive

 

 

Biography:

Noh Jong Ho has been serving as Internal Auditor of Green Cross Corporation since March 12, 2010. Noh currently serves as an advisor of Green Cross Holdings. Previously, Noh was Assistant Managing Director of Samsung Electronics Co., Ltd. Noh holds a Bachelor's degree in Science from Korea University.

Age: 53

Education:

Korea University, B (Science)

 

Significant Developments

 

 

 

Green Cross Corp Announces Share Repurchase

Aug 27, 2013


Green Cross Corp announced that its has decided to repurchase 100,000 shares of its common stock from August 28, 2013 to November 27, 2013 for KRW 12,300 million, to stabilize its stock price.

Green Cross Corp Announces Amendments to Rights Issue

May 28, 2013


Green Cross Corp announced that it has made amendments to the previously announced rights issue of 1 million common shares. After the amendments, the shares will be issued at an issue price of KRW 107,000 per share, raising KRW 107,000 million for facilities.

Green Cross Corp Announces Amendments to Rights Issue

May 27, 2013


Green Cross Corp announced that it has made amendments to the previously announced rights issue of 1 million common shares. After the amendments, the shares will be issued at an issue price of KRW 107,500 per share, raising KRW 107,500 million for facilities.

Green Cross Corp Announces Amendments to Rights Issue

Apr 17, 2013


Green Cross Corp announced that it has made amendments to the previously announced rights issue of 1 million common shares. After the amendments, the shares will be issued at an issue price of KRW 119,500 per share, raising KRW 119,500 million for facilities.

Green Cross Corp Announces Rights Issue and Issuance of Bonus Shares

Apr 04, 2013


Green Cross Corp announced a rights issue of 1 million common shares of par value KRW 5,000 each at an issue price of KRW 122,000 per share, raising KRW 122 billion for facilities. The employee stock ownership association will have a preferred right to purchase the new shares at an allocation rate of 20% on May 30, 2013, and the shareholders of record on April 22, 2013 will have rights to purchase 0.0791218346 new rights shares for each share held from May 30, 2013 to May 31, 2013. The listing date of the new shares is June 20, 2013. Korea Investment & Securities Co., Ltd. will be the underwriter. The Company also announced that its Board of Directors has decided the issuance of bonus shares to all shareholders in the ratio of 0.05:1 (0.05 bonus shares for each share held). The Company will issue 555,549 new shares of par value KRW 5,000 each as bonus shares to the shareholders of record on June 10, 2013. The listing date of the new shares is June 28, 2013.

Green Cross Corp Declares Annual Cash Dividend for FY 2012

Feb 05, 2013


Green Cross Corp announced that it has declared an annual cash dividend of KRW 1,250 per share of common stock to shareholders of record on December 31, 2012 for the fiscal year 2012. The dividend rate of market price is 0.9% and the total amount of the cash dividend is KRW 12,638,736,250. The dividend is expected to be paid on March 29, 2013. The Company's annual cash dividend for the fiscal year 2011 was KRW 1,500 per share of common stock.

Green Cross Corp Signs Contract with Thai Red Cross Society

Jan 04, 2013


Green Cross Corp announced that it has signed a contract with Thai Red Cross Society to supply construction service. The contract amount is KRW 72,844,768,800.

Green Cross Corp Signs Contract with Thai Red Cross Society

Jan 04, 2013


Green Cross Corp announced that it has signed a contract with Thai Red Cross Society to supply construction service. The contract amount is KRW 72,844,768,800.

Green Cross Corp Signs Contract with PAHO

Dec 24, 2012


Green Cross Corp announced that it has signed a contract with PAHO to supply flu vaccine. The contract amount is KRW 13,046,777,380.

Ildong Pharmaceutical Co., Ltd. Announces Changes in Shareholding Structure

Dec 10, 2012


Ildong Pharmaceutical Co., Ltd. announced that Green Cross Corporation has acquired 1,770,000 shares of Ildong Pharmaceutical, equivalent to a 7.07% stake. After the transaction, Green Cross Corporation and one related party's combined stake in Ildong Pharmaceutical has increased to 15.35% from 8.28%.

 

 

News

 

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013 - New Market Study Published
UK PRWire (704 Words)

09-Oct-2013

New Market Study, "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013", Has Been Published
SBWire (756 Words)

09-Oct-2013

PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF LONICERA JAPONICA FOR PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE
European Patents (118 Words)

08-Oct-2013

Trials begin on liver cancer drug
Hospital Pharmacy Europe (191 Words)

08-Oct-2013

USPTO ISSUES TRADEMARK: STRATEGEE RESEARCH + SOFTWARE + CONSULTING
U.S. Fed News (203 Words)

08-Oct-2013

Greg Tassell And Gary Branch
Cranbrook People (158 Words)

06-Oct-2013

A Portrait Of A Marriage In Books: Talk
Cranbrook People (177 Words)

05-Oct-2013

WIPO PUBLISHES PATENT OF GREEN CROSS AND MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE FOR "EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND...
U.S. Fed News (294 Words)

05-Oct-2013

The Exchange is Open ... Now What?
90.5 WESA (425 Words)

03-Oct-2013

Influenza a Infections - Pipeline Review, H2 2013 - New Market Report
SBWire (738 Words)

03-Oct-2013

RESEARCH AND MARKETS: Pertussis - Pipeline Review, H2 2013
4 Traders (267 Words)

03-Oct-2013

 


 

Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

 

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

 

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

 

Filed Currency

KRW

KRW

KRW

KRW

KRW

 

Exchange Rate (Period Average)

1126.848795

1107.891393

1156.281981

1276.385219

1100.562842

 

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

 

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

 

 

    Net Sales

720.4

693.1

685.9

503.9

468.9

 

Revenue

720.4

693.1

685.9

503.9

468.9

 

Total Revenue

720.4

693.1

685.9

503.9

468.9

 

 

 

 

 

 

 

 

    Cost of Revenue

495.4

459.5

407.4

292.6

283.4

 

Cost of Revenue, Total

495.4

459.5

407.4

292.6

283.4

 

Gross Profit

225.0

233.6

278.4

211.3

185.6

 

 

 

 

 

 

 

 

    Selling/General/Administrative Expense

39.3

41.8

38.8

28.9

35.7

 

    Labor & Related Expense

40.4

43.8

43.0

36.2

40.6

 

    Advertising Expense

13.5

14.0

11.3

13.7

11.7

 

Total Selling/General/Administrative Expenses

93.3

99.5

93.2

78.7

88.0

 

Research & Development

63.0

54.3

48.0

35.1

31.3

 

    Depreciation

2.1

2.0

1.7

2.5

3.4

 

    Amortization of Intangibles

0.6

0.7

0.7

1.4

1.2

 

Depreciation/Amortization

2.8

2.7

2.4

3.9

4.6

 

        Investment Income - Operating

-

-

0.5

-

-

 

    Interest/Investment Income - Operating

-

-

0.5

-

-

 

Interest Expense (Income) - Net Operating Total

-

-

0.5

-

-

 

    Loss (Gain) on Sale of Assets - Operating

-

-

0.1

-

-

 

Unusual Expense (Income)

-

-

0.1

-

-

 

    Other Operating Expense

-

-

6.9

-

-

 

    Other, Net

-

-

-4.4

-

-

 

Other Operating Expenses, Total

-

-

2.5

-

-

 

Total Operating Expense

654.4

616.1

554.1

410.4

407.2

 

 

 

 

 

 

 

 

Operating Income

66.0

77.1

131.7

93.5

61.7

 

 

 

 

 

 

 

 

        Interest Expense - Non-Operating

-1.9

-3.1

-4.9

-7.5

-6.1

 

    Interest Expense, Net Non-Operating

-1.9

-3.1

-4.9

-7.5

-6.1

 

        Interest Income - Non-Operating

0.7

2.8

1.3

0.9

0.8

 

        Investment Income - Non-Operating

-1.7

-1.8

-1.8

0.6

3.6

 

    Interest/Investment Income - Non-Operating

-0.9

1.0

-0.5

1.5

4.4

 

    Interest Income (Expense) - Net Non-Operating

0.0

0.0

0.0

-

-

 

Interest Income (Expense) - Net Non-Operating Total

-2.8

-2.0

-5.4

-6.0

-1.7

 

Gain (Loss) on Sale of Assets

-0.2

-0.2

-

-0.8

0.1

 

    Other Non-Operating Income (Expense)

1.9

2.9

-

-4.7

-6.4

 

Other, Net

1.9

2.9

-

-4.7

-6.4

 

Income Before Tax

64.9

77.7

126.3

82.0

53.8

 

 

 

 

 

 

 

 

Total Income Tax

15.5

25.7

27.8

18.9

9.4

 

Income After Tax

49.4

52.0

98.6

63.1

44.4

 

 

 

 

 

 

 

 

    Minority Interest

-1.7

-2.0

-0.2

-

-

 

Net Income Before Extraord Items

47.6

50.0

98.3

63.1

44.4

 

Net Income

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

 

 

Income Available to Common Excl Extraord Items

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

 

 

Income Available to Common Incl Extraord Items

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

 

 

Basic/Primary Weighted Average Shares

10.8

10.7

10.1

9.7

9.6

 

Basic EPS Excl Extraord Items

4.41

4.69

9.75

6.52

4.63

 

Basic/Primary EPS Incl Extraord Items

4.41

4.69

9.75

6.52

4.63

 

Dilution Adjustment

0.0

0.0

1.0

0.2

0.0

 

Diluted Net Income

47.6

50.0

99.4

63.3

44.4

 

Diluted Weighted Average Shares

10.8

10.7

10.3

9.7

9.6

 

Diluted EPS Excl Extraord Items

4.41

4.69

9.63

6.51

4.63

 

Diluted EPS Incl Extraord Items

4.41

4.69

9.63

6.51

4.63

 

Dividends per Share - Common Stock Primary Issue

1.04

1.27

1.42

0.90

0.84

 

Gross Dividends - Common Stock

11.2

13.7

14.8

8.8

8.0

 

Interest Expense, Supplemental

1.9

3.1

4.9

7.5

6.1

 

Depreciation, Supplemental

12.1

10.1

7.8

11.4

8.3

 

Total Special Items

0.2

0.2

0.1

0.8

-0.1

 

Normalized Income Before Tax

65.1

77.9

126.4

82.8

53.6

 

 

 

 

 

 

 

 

Effect of Special Items on Income Taxes

0.1

0.1

0.0

0.2

0.0

 

Inc Tax Ex Impact of Sp Items

15.6

25.8

27.8

19.1

9.4

 

Normalized Income After Tax

49.5

52.2

98.6

63.7

44.3

 

 

 

 

 

 

 

 

Normalized Inc. Avail to Com.

47.8

50.1

98.4

63.7

44.3

 

 

 

 

 

 

 

 

Basic Normalized EPS

4.42

4.70

9.76

6.58

4.62

 

Diluted Normalized EPS

4.42

4.70

9.64

6.57

4.62

 

Amort of Intangibles, Supplemental

1.8

1.7

1.6

1.8

1.2

 

Rental Expenses

2.1

2.1

1.9

1.7

1.9

 

Advertising Expense, Supplemental

13.5

14.0

11.3

13.7

11.7

 

Research & Development Exp, Supplemental

63.0

54.3

48.0

35.1

31.3

 

Normalized EBIT

66.0

77.1

132.4

93.5

61.7

 

Normalized EBITDA

79.9

88.8

141.8

106.7

71.2

 

 

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

Filed Currency

KRW

KRW

KRW

KRW

KRW

Exchange Rate

1066.400024

1152

1134.9

1164.475

1259.55

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Equivalents

21.3

28.0

27.7

19.1

9.2

    Short Term Investments

6.2

45.9

92.2

37.3

0.1

Cash and Short Term Investments

27.5

74.0

119.8

56.4

9.3

        Accounts Receivable - Trade, Gross

205.1

190.9

138.2

147.1

130.3

        Provision for Doubtful Accounts

-0.9

-1.4

-1.5

-3.3

-3.2

    Trade Accounts Receivable - Net

204.2

189.6

137.1

143.9

127.0

    Other Receivables

1.0

0.8

0.9

1.1

0.8

Total Receivables, Net

205.2

190.5

138.0

145.0

127.9

    Inventories - Finished Goods

70.4

70.8

73.1

67.5

37.9

    Inventories - Work In Progress

104.8

80.1

79.7

79.7

37.3

    Inventories - Raw Materials

22.4

21.1

19.4

34.6

14.1

    Inventories - Other

1.6

3.2

2.0

1.7

1.7

Total Inventory

199.2

175.2

174.1

183.4

90.9

Prepaid Expenses

0.9

0.9

1.2

0.6

1.0

    Deferred Income Tax - Current Asset

-

-

-

2.5

1.2

    Other Current Assets

0.0

0.7

1.7

8.8

11.4

Other Current Assets, Total

0.0

0.7

1.7

11.4

12.6

Total Current Assets

432.8

441.2

434.8

396.8

241.7

 

 

 

 

 

 

        Buildings

171.0

145.2

137.1

135.9

47.2

        Land/Improvements

17.3

15.6

15.8

6.4

5.9

        Machinery/Equipment

106.9

93.7

82.0

78.6

50.8

        Construction in Progress

58.2

21.3

11.8

2.1

91.7

        Other Property/Plant/Equipment

21.2

17.9

15.8

-

-

    Property/Plant/Equipment - Gross

374.6

293.7

262.5

223.0

195.6

    Accumulated Depreciation

-92.6

-75.3

-67.8

-54.5

-40.2

Property/Plant/Equipment - Net

282.1

218.4

194.8

168.4

155.4

Goodwill, Net

10.4

9.7

8.5

-

-

Intangibles, Net

25.6

17.0

10.1

11.5

11.3

    LT Investment - Affiliate Companies

13.3

0.9

0.4

18.7

6.1

    LT Investments - Other

123.9

54.4

23.2

10.7

15.8

Long Term Investments

137.2

55.3

23.6

29.3

21.9

    Deferred Income Tax - Long Term Asset

0.3

0.2

1.2

-

0.1

    Other Long Term Assets

6.6

5.1

4.4

6.2

5.8

Other Long Term Assets, Total

6.9

5.2

5.7

6.2

5.9

Total Assets

895.0

746.8

677.4

612.3

436.2

 

 

 

 

 

 

Accounts Payable

71.1

77.7

48.5

86.9

38.5

Accrued Expenses

22.6

21.1

23.7

20.6

15.4

Notes Payable/Short Term Debt

69.3

24.7

63.4

5.0

66.4

Current Portion - Long Term Debt/Capital Leases

-

-

-

38.8

11.9

    Dividends Payable

-

-

-

0.0

0.0

    Customer Advances

3.1

1.7

1.7

43.9

2.1

    Security Deposits

0.6

0.6

0.4

0.4

0.3

    Income Taxes Payable

9.1

10.2

15.7

20.0

3.9

    Other Payables

14.1

12.4

5.6

1.4

7.3

    Other Current Liabilities

20.1

17.3

16.0

14.2

8.9

Other Current liabilities, Total

46.9

42.2

39.4

79.9

22.6

Total Current Liabilities

210.0

165.7

174.9

231.2

154.7

 

 

 

 

 

 

    Long Term Debt

7.6

8.0

3.6

63.5

61.0

Total Long Term Debt

7.6

8.0

3.6

63.5

61.0

Total Debt

77.0

32.8

67.0

107.3

139.2

 

 

 

 

 

 

    Deferred Income Tax - LT Liability

5.5

1.6

0.6

1.7

-

Deferred Income Tax

5.5

1.6

0.6

1.7

-

Minority Interest

12.6

10.5

7.0

-

-

    Pension Benefits - Underfunded

21.2

16.3

12.7

6.6

7.3

    Other Long Term Liabilities

8.0

8.1

1.6

1.2

1.1

Other Liabilities, Total

29.2

24.4

14.4

7.8

8.4

Total Liabilities

265.0

210.2

200.4

304.2

224.0

 

 

 

 

 

 

    Common Stock

47.5

44.0

43.2

38.7

35.8

Common Stock

47.5

44.0

43.2

38.7

35.8

Additional Paid-In Capital

190.6

176.4

145.5

78.1

66.8

Retained Earnings (Accumulated Deficit)

361.0

302.3

274.8

179.6

109.1

Treasury Stock - Common

-0.5

-0.5

-0.5

-0.5

-3.7

Unrealized Gain (Loss)

20.7

4.5

3.8

2.1

3.0

    Translation Adjustment

-0.4

-0.3

0.0

-

-

    Other Equity

11.1

10.2

10.4

10.1

1.1

    Other Comprehensive Income

0.0

0.1

-0.1

-

-

Other Equity, Total

10.6

10.0

10.3

10.1

1.1

Total Equity

630.0

536.6

477.0

308.1

212.1

 

 

 

 

 

 

Total Liabilities & Shareholders’ Equity

895.0

746.8

677.4

612.3

436.2

 

 

 

 

 

 

    Shares Outstanding - Common Stock Primary Issue

10.8

10.8

10.4

9.8

9.6

Total Common Shares Outstanding

10.8

10.8

10.4

9.8

9.6

Treasury Shares - Common Stock Primary Issue

0.0

0.0

0.0

0.0

0.2

Employees

1,457

1,335

1,374

1,341

1,285

Number of Common Shareholders

-

-

14,390

23,102

2,171

Accumulated Intangible Amort, Suppl.

9.2

6.8

5.4

-

-

Deferred Revenue - Current

3.1

1.7

1.7

43.9

2.1

Deferred Revenue - Long Term

7.0

6.9

-

-

-

Total Long Term Debt, Supplemental

-

10.0

4.0

38.8

11.9

Long Term Debt Maturing within 1 Year

-

3.3

0.2

38.8

11.9

Long Term Debt Maturing in Year 2

-

3.3

1.9

-

-

Long Term Debt Maturing in Year 3

-

3.3

1.9

-

-

Long Term Debt Maturing in 2-3 Years

-

6.7

3.8

-

-

Long Term Debt Matur. in Year 6 & Beyond

-

0.0

0.0

0.0

0.0

 

 

Annual Cash Flows

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

Filed Currency

KRW

KRW

KRW

KRW

KRW

Exchange Rate (Period Average)

1126.848795

1107.891393

1156.281981

1276.385219

1100.562842

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

Net Income/Starting Line

49.4

52.0

98.6

63.1

44.4

    Depreciation

12.1

10.1

7.8

11.4

8.3

Depreciation/Depletion

12.1

10.1

7.8

11.4

8.3

    Amortization of Intangibles

1.8

1.7

1.6

1.8

1.2

Amortization

1.8

1.7

1.6

1.8

1.2

Deferred Taxes

-

-

-

1.2

-1.2

    Unusual Items

-0.3

0.3

-0.1

3.2

-21.7

    Equity in Net Earnings (Loss)

2.7

0.7

1.9

1.0

-0.4

    Other Non-Cash Items

24.8

34.5

37.3

2.4

21.5

Non-Cash Items

27.1

35.4

39.1

6.6

-0.7

    Accounts Receivable

0.0

-57.0

21.3

-6.3

-34.4

    Inventories

-9.1

-3.7

21.7

-79.0

-27.5

    Prepaid Expenses

0.1

-0.4

0.2

0.5

-0.8

    Other Assets

-

-

-

-0.1

0.0

    Accounts Payable

-11.5

38.1

-35.4

35.5

-8.4

    Accrued Expenses

1.5

-2.2

0.9

3.3

3.4

    Taxes Payable

-1.7

0.6

-0.5

14.7

-3.1

    Other Liabilities

-5.6

2.3

-48.1

35.1

-0.1

    Other Operating Cash Flow

-19.0

-27.3

-33.7

-

-

Changes in Working Capital

-45.3

-49.7

-73.6

3.7

-70.9

Cash from Operating Activities

45.0

49.5

73.5

87.8

-18.8

 

 

 

 

 

 

    Purchase of Fixed Assets

-57.9

-39.3

-24.8

-11.8

-52.0

    Purchase/Acquisition of Intangibles

-7.3

-10.4

-1.8

-3.6

-5.7

Capital Expenditures

-65.2

-49.7

-26.6

-15.4

-57.7

    Acquisition of Business

-

-

-1.5

-

-

    Sale of Fixed Assets

0.7

1.8

0.3

0.2

1.3

    Sale/Maturity of Investment

45.9

113.8

39.1

5.5

18.9

    Purchase of Investments

-60.5

-100.2

-88.2

-45.9

-6.7

    Sale of Intangible Assets

0.0

0.0

2.0

-

0.1

    Other Investing Cash Flow

-1.1

-0.7

-0.2

0.0

-1.0

Other Investing Cash Flow Items, Total

-15.0

14.8

-48.5

-40.2

12.6

Cash from Investing Activities

-80.2

-34.9

-75.1

-55.6

-45.0

 

 

 

 

 

 

    Other Financing Cash Flow

0.3

2.9

0.6

-11.7

-9.1

Financing Cash Flow Items

0.3

2.9

0.6

-11.7

-9.1

Total Cash Dividends Paid

-13.7

-15.7

-9.9

-6.9

-8.0

        Sale/Issuance of Common

-

0.5

54.6

11.4

0.2

    Common Stock, Net

-

0.5

54.6

11.4

0.2

    Warrants Converted

-

27.1

-

-

-

Issuance (Retirement) of Stock, Net

-

27.5

54.6

11.4

0.2

        Short Term Debt Issued

73.0

31.7

7.8

5.5

58.7

        Short Term Debt Reduction

-33.5

-41.6

-43.5

-65.5

-

    Short Term Debt, Net

39.5

-9.9

-35.7

-60.0

58.7

        Long Term Debt Issued

0.5

9.4

-

46.9

27.3

        Long Term Debt Reduction

-

-28.0

-1.6

-3.5

-

    Long Term Debt, Net

0.5

-18.7

-1.6

43.3

27.3

Issuance (Retirement) of Debt, Net

40.0

-28.6

-37.3

-16.6

86.0

Cash from Financing Activities

26.6

-13.9

8.0

-23.9

69.1

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

-0.1

-

-

Net Change in Cash

-8.5

0.8

6.3

8.3

5.2

 

 

 

 

 

 

Net Cash - Beginning Balance

28.6

28.3

20.9

9.1

5.3

Net Cash - Ending Balance

20.1

29.1

27.1

17.4

10.5

Cash Interest Paid

1.9

1.6

2.4

-

-

Cash Taxes Paid

18.2

28.8

32.5

-

-

 

 

Annual Income Statement

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

Filed Currency

KRW

KRW

KRW

KRW

KRW

Exchange Rate (Period Average)

1126.848795

1107.891393

1156.281981

1276.385219

1100.562842

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

    Sales Revenue of Merchandises

-

-

-

194.6

221.9

    Finished Products

-

-

-

308.9

246.1

    Services Revenue

-

-

-

0.4

0.9

    Sales Revenue

720.4

693.1

685.9

-

-

Total Revenue

720.4

693.1

685.9

503.9

468.9

 

 

 

 

 

 

    Costs of Goods & Services Sold

495.4

459.5

407.4

-

-

    Cost of Merchandises Sold

-

-

-

154.4

158.7

    Cost of Finished Goods Sold

-

-

-

137.9

123.7

    Cost of Services

-

-

-

0.4

0.9

    Salaries & Wages

31.2

33.1

31.4

24.9

30.6

    Retirement & Severance Benefits

3.9

3.6

3.3

2.4

3.6

    Employee Benefits

2.0

3.6

5.5

6.0

3.8

    Welfare Expense

3.3

3.5

2.8

2.9

2.6

    Travel Expense

6.4

6.1

5.3

5.0

4.9

    Communication Expense

-

-

0.4

0.3

0.3

    Utility Expense

0.6

0.6

0.4

0.4

0.4

    Consumable Expense

1.3

0.8

0.6

1.1

1.8

    Taxes & Dues

0.6

1.0

0.5

0.5

0.6

    Repair Expense

-

-

-

0.0

0.1

    Insurance Premiums

-

-

-

0.1

0.1

    Vehicle Maintenance Expense

0.9

0.9

0.7

0.6

0.8

    Entertainment Expense

2.3

1.3

1.2

0.8

0.9

    Shipping & Handling Expense

4.3

3.8

4.6

2.4

2.2

    Publication Expense

-

-

-

0.1

0.2

    Education & Training Expense

-

-

0.6

0.5

0.7

    Commissions

11.0

15.6

14.7

10.8

9.8

    Rental Expense

2.1

2.1

1.9

1.7

1.9

    Advertising Expense

8.5

7.8

6.0

6.0

6.2

    Sales Promotional Expense

5.0

6.2

5.3

7.6

5.5

    Overseas Market Development Cost

1.3

1.3

0.9

0.4

0.3

    Market Development Expense

-

-

-

-

5.9

    Depreciation

2.1

2.0

1.7

2.5

3.4

    Amort. of Intangibless

0.6

0.7

0.7

1.4

1.2

    Expense of Allow. for DA

0.1

0.2

-

-

0.5

    Sample Expense

0.4

1.0

0.7

0.4

0.6

    Conference Expense

-

-

0.3

0.2

0.4

    Development Expense

-

-

-

35.1

31.3

    R & D Expense

63.0

54.3

48.0

-

-

    Packaging Expense

-

-

-

0.2

0.2

    Consignment Service Commission

4.9

4.5

4.1

2.7

2.6

    Export Sales Commission

-

-

-

0.7

0.5

    Miscellaneous Service Commission

-

-

-

0.0

0.0

    Exporting Commission

-

-

1.1

-

-

    Other Selling & Administrative Expense

3.3

2.6

0.7

-

-

    Rental Income

-

-

-1.0

-

-

    Gain on Foreign Currency Translation

-

-

-0.4

-

-

    Gain on Foreign Currency Transaction

-

-

-1.9

-

-

    Gain on Disposal of PPE

-

-

0.0

-

-

    Reversal of Allow. for DA

-

-

-0.4

-

-

    Commission Income

-

-

-1.2

-

-

    Miscellaneous Income

-

-

-1.7

-

-

    Other Operating Income

-

-

-0.1

-

-

    Loss on Foreign Currency Transaction

-

-

1.9

-

-

    Loss on Foreign Currency Translation

-

-

0.3

-

-

    Loss on Disposal of PPE

-

-

0.0

-

-

    Loss on Disposal of Intangibless

-

-

0.1

-

-

    Loss on Disposal of Invmt in Real Estate

-

-

0.6

-

-

    Donations Paid

-

-

6.0

-

-

    Other Allow. for DA

-

-

0.2

-

-

    Miscellaneous Loss

-

-

0.7

-

-

    Adj. for Other Selling & Admin. Expense

0.0

0.0

0.0

-

-

    Adj. for Other Operating Income

-

-

0.0

-

-

    Adj. for Other Operating Expense

-

-

0.0

-

-

Total Operating Expense

654.4

616.1

554.1

410.4

407.2

 

 

 

 

 

 

    Interest Income

0.7

2.8

1.3

0.9

0.8

    Dividend Income

0.4

0.1

0.1

0.1

0.3

    Rental Income

0.5

0.5

-

1.2

1.3

    Gain on Foreign Currency Transaction

0.0

0.3

-

3.6

1.8

    Gain on Foreign Currency Translation

0.4

0.0

0.8

4.7

0.9

    Gain-Valuation of Currency Swap

-

-

-

-

15.0

    Gain on Valuations of Derivatives

-

0.0

-

-

-

    Gain on Derivatives Transaction

0.1

0.0

-

-

-

    Gain Disposal Assets

0.1

0.1

-

0.1

0.1

    Reversal of Allow. for DA

-

-

-

0.0

0.1

    Commission Income

1.2

1.0

-

1.1

1.4

    G-Inv.Asset Disposal

-

-

-

4.6

7.0

    Gain-Currency Swap Transaction

-

-

-

-

0.1

    Gain-Disposal of F.A. Avail. for Sale

0.6

-

0.2

-

-

    Miscellaneous Income

0.9

4.1

-

0.1

0.1

    Interest Expense

-1.9

-3.1

-4.9

-7.5

-6.1

    Loss-Disposal of Sec. Avail. for Sale

-

-

0.0

-0.5

-0.3

    Other Allow. for DA

0.0

-

-

-0.2

0.0

    Disp of Inv. Assets

-

-

-

-1.4

-

    Loss-Currency Swap Transaction

-

-

-

-0.8

-0.1

    Loss on Derivative Transaction

-

-0.1

-0.5

-

-

    Loss Disp Tang. Ast

-0.3

-0.4

-

-0.1

0.0

    Loss-Scrapping of inventory

-

-

-

-0.8

-

    Loss on Foreign Currency Transaction

0.0

-0.1

0.0

-2.5

-5.7

    Loss on Foreign Currency Translation

0.0

-0.1

-0.3

-0.2

-15.7

    Donations

-0.4

-1.3

-

-3.5

-1.2

    Factory Transfrt Expense

-

-

-

-3.4

-7.5

    Miscellaneous Losses

-0.2

-1.4

-

-0.1

-0.5

    Loss-Disposal of Accounts Receivable

-

-

-

0.0

-

    L-Currency Swap Valuation

-

-

-

-3.5

-

    Loss on Valt of Other Derivatives

-

-

-0.3

-

-

    Loss-Reduction of Intangible Assets

-

-

-

-2.5

-

    Loss on Redemption of Bonds

-

-1.3

-

-

-

    Gain under Equity Method

-

-

-

0.5

0.5

    Loss-Valuation of Equity Method Sec.

-

-

-

-1.5

-0.1

    Loss on Invmt in Affiliates

-2.7

-0.7

-1.9

-

-

    Adj. for Finance Income

0.0

0.0

0.0

-

-

    Adj. for Finance Expense

0.0

0.0

0.0

-

-

    Gain on Foreign Currency Translation, Ot

0.2

0.2

-

-

-

    Gain on Foreign Currency Transaction, Ot

1.2

1.4

-

-

-

    Gain on Disposal of Intangibless

-

0.0

-

-

-

    Adj. for Other Non-Operating Income

0.0

0.0

-

-

-

    Loss on Foreign Currency Transaction, Ot

-1.4

-1.3

-

-

-

    Loss on Foreign Currency Translation, Ot

-0.4

-0.3

-

-

-

    Impairment Loss on PPE

-

0.0

-

-

-

    Loss on Disposal of Intangibless

0.0

-

-

-

-

    Adj. for Other Non-Operating Expense

0.0

0.0

-

-

-

Net Income Before Taxes

64.9

77.7

126.3

82.0

53.8

 

 

 

 

 

 

Prov. for Income Taxes

15.5

25.7

27.8

18.9

9.4

Net Income After Taxes

49.4

52.0

98.6

63.1

44.4

 

 

 

 

 

 

    Minority Interest

-1.7

-2.0

-0.2

-

-

Net Income Before Extra. Items

47.6

50.0

98.3

63.1

44.4

Net Income

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

Income Available to Com Excl ExtraOrd

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

Income Available to Com Incl ExtraOrd

47.6

50.0

98.3

63.1

44.4

 

 

 

 

 

 

Basic Weighted Average Shares

10.8

10.7

10.1

9.7

9.6

Basic EPS Excluding ExtraOrdinary Items

4.41

4.69

9.75

6.52

4.63

Basic EPS Including ExtraOrdinary Items

4.41

4.69

9.75

6.52

4.63

Dilution Adjustment

0.0

0.0

1.0

0.2

0.0

Diluted Net Income

47.6

50.0

99.4

63.3

44.4

Diluted Weighted Average Shares

10.8

10.7

10.3

9.7

9.6

Diluted EPS Excluding ExtraOrd Items

4.41

4.69

9.63

6.51

4.63

Diluted EPS Including ExtraOrd Items

4.41

4.69

9.63

6.51

4.63

DPS-Ordinary Shares

1.04

1.27

1.42

0.90

0.84

Gross Dividends - Common Stock

11.2

13.7

14.8

8.8

8.0

Normalized Income Before Taxes

65.1

77.9

126.4

82.8

53.6

 

 

 

 

 

 

Inc Tax Ex Impact of Sp Items

15.6

25.8

27.8

19.1

9.4

Normalized Income After Taxes

49.5

52.2

98.6

63.7

44.3

 

 

 

 

 

 

Normalized Inc. Avail to Com.

47.8

50.1

98.4

63.7

44.3

 

 

 

 

 

 

Basic Normalized EPS

4.42

4.70

9.76

6.58

4.62

Diluted Normalized EPS

4.42

4.70

9.64

6.57

4.62

Interest Expense, Supplemental

1.9

3.1

4.9

7.5

6.1

Rental Expense, Supplemental

2.1

2.1

1.9

1.7

1.9

Advertising Expense, Supplemental

13.5

14.0

11.3

13.7

11.7

R&D Expense, Supplemental

63.0

54.3

48.0

35.1

31.3

Depreciation, Supplemental

12.1

10.1

7.8

11.4

8.3

Amort of Intangibles, Supplemental

1.8

1.7

1.6

1.8

1.2

 

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

UpdateType/Date

Updated Normal
31-Dec-2012

Reclassified Normal
31-Dec-2012

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

Filed Currency

KRW

KRW

KRW

KRW

KRW

Exchange Rate

1066.400024

1152

1134.9

1164.475

1259.55

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

    Cash & Cash Equivalents

21.3

28.0

27.7

19.1

9.2

    Current Fincl Instrm

6.2

45.9

92.2

37.3

0.1

    Current Derivative Assets

-

0.7

1.7

8.8

11.4

    Trade Receivable, Gross

205.1

190.9

138.2

147.1

130.3

    Allow. for DA for Trade Receivable

-0.9

-1.4

-1.5

-3.3

-3.2

    Account Receivable

0.8

0.7

0.8

1.1

0.8

    Accrued Income

0.1

0.1

0.4

0.1

0.0

    Advance Payments

1.6

3.2

2.0

1.7

1.6

    Prepaid Expense

0.9

0.9

0.5

0.6

1.0

    Marketable Secs.

-

-

-

-

0.0

    Current Loans

0.2

0.1

0.1

-

-

    Prepaid Value Added Taxes

-

0.1

0.7

-

-

    Deferred Income Tax

-

-

-

2.5

1.2

    Merchandises

39.9

41.2

43.8

40.4

28.0

    Finished Goods

25.5

21.0

25.3

16.6

9.2

    Work in Progress

104.8

80.1

79.7

79.7

37.3

    Raw Materials

22.4

21.1

19.4

34.6

14.1

    Supplies

-

-

-

0.0

0.0

    Goods in Transit

4.9

8.6

4.0

10.5

0.6

    Adj. for Trade & Other Receivable

0.0

0.0

0.0

-

-

    Adj. for Inventories

0.0

0.0

0.0

-

-

    Adj. for Other Current Assets

0.0

0.0

0.0

-

-

Total Current Assets

432.8

441.2

434.8

396.8

241.7

 

 

 

 

 

 

    LT Finl Assets

0.5

0.0

-

2.5

0.4

    Other Non-Current Fincl Instrm

-

-

17.1

-

-

    Secs for Sale

117.0

48.4

-

8.2

15.3

    Invmt in Affiliates

13.3

0.9

0.4

18.7

6.1

    Guarantee Deposits, Non-Current Assets

6.6

5.1

4.4

6.2

5.8

    Non-Current Deferred Income Taxes Assets

0.3

0.2

1.2

-

0.1

    Invmt in Properties

6.4

6.0

6.1

-

-

    Lands

17.3

15.6

15.8

6.4

5.9

    Buildings

-

-

-

133.0

46.5

    Buildings Depre.

-

-

-

-9.0

-6.3

    Structures

-

-

-

2.9

0.7

    Structure Depre.

-

-

-

-0.3

-0.2

    Buildings & Structures

171.0

145.2

137.1

-

-

    Buildings & Structures-Depreciation

-18.8

-14.3

-11.7

-

-

    Machineries & Equipments

106.9

93.7

82.0

67.0

40.9

    Machineries & Equipments-Depreciation

-59.5

-49.4

-45.2

-36.7

-25.9

    Transport Equip.

-

-

-

1.8

1.4

    Transport Deprec

-

-

-

-1.0

-0.8

    Tools

-

-

-

9.7

8.5

    Tool/Equip Depr.

-

-

-

-7.5

-6.9

    Construction in Progress

58.2

21.3

11.8

2.1

91.7

    Other Property Plant & Equipment

21.2

17.9

15.8

-

-

    Other Tangible Assets-Depreciation

-14.3

-11.6

-10.8

-

-

    Industrial Property Rights

2.4

1.9

0.7

1.8

2.1

    Development Costs

5.7

5.4

6.5

7.1

7.6

    Goodwill

10.4

9.7

8.5

-

-

    Other Intangibless

17.6

9.7

2.9

2.6

1.6

    Adj. for Property, Plant & Equipment

0.0

0.0

0.0

-

-

    Adj. for Intangibless

0.0

0.0

0.0

-

-

    Adj. for Other Non-Current Fincl Instrm

0.0

0.0

-

-

-

Total Assets

895.0

746.8

677.4

612.3

436.2

 

 

 

 

 

 

    Other Payable

14.1

12.4

5.6

1.4

7.3

    Current Trade Payable

71.1

77.7

48.5

86.9

38.5

    Current Borrowings

69.3

24.7

63.4

5.0

66.4

    Current Portion of Long-term Liabilities

-

-

-

38.8

11.9

    Accrued Expense

21.5

18.3

20.9

18.0

13.3

    Withheld

-

-

-

7.6

4.4

    Withheld(1)

2.2

2.1

2.1

-

-

    Advance from Customers, Current

1.9

1.7

1.7

43.9

2.1

    Unearned Income

1.2

-

-

-

-

    Dividend Payablee

-

-

-

0.0

0.0

    Current Tax Liabilities

9.1

10.2

15.7

20.0

3.9

    Value Added Taxes Withheld

1.1

2.7

2.8

2.6

2.0

    Guarantee Deposit Withheld

0.5

0.6

0.4

0.4

0.3

    Fincl Guarantee Deposits Liabilities

0.1

-

-

-

-

    Special R&D Withheld

8.5

7.7

5.6

-

-

    Prov. for Other Estimated Liability

9.4

7.5

8.2

6.5

4.2

    Current Derivatives Liabilities

-

-

-

0.2

0.3

    Current Derivatives Liabilities(1)

-

-

0.1

-

-

    Adj. for Current Trade & Other Payable

0.0

0.0

0.0

-

-

    Adj. for Other Current Liabilities

0.0

0.0

0.0

-

-

Total Current Liabilities

210.0

165.7

174.9

231.2

154.7

 

 

 

 

 

 

    Non-Current Borrowings

7.6

8.0

3.6

19.4

61.0

    Bonds with Warrant

-

-

-

21.9

-

    Convertible Bonds

-

-

-

22.2

-

Total Long Term Debt

7.6

8.0

3.6

63.5

61.0

 

 

 

 

 

 

    Non-Current Trade & Other Payable

-

-

0.9

-

-

    LT Accounts Pay

0.2

0.4

-

-

-

    Non-Current Fixed Benefit Liabilities

21.2

16.3

12.7

-

-

    Prov.for Retirement & Severance Benefits

-

-

-

22.5

7.3

    Deposit-Retirement Insurance

-

-

-

-15.9

-

    Transfer to National Pension Fund

-

-

-

-0.1

-

    Lease Guarantee

-

-

-

1.2

1.1

    Non-Current Unearned Income

7.0

6.9

-

-

-

    Deferred Income Taxes, LT Liabilities

5.5

1.6

0.6

1.7

-

    Minority Interst

12.6

10.5

7.0

-

-

    Other Non-Current Prov.s

-

-

0.7

-

-

    Rental Guarantee Deposit, LT Liabilities

0.8

0.9

-

-

-

    Adj. for LT Trade & Other Payable

0.0

0.0

-

-

-

Total Liabilities

265.0

210.2

200.4

304.2

224.0

 

 

 

 

 

 

    Capital Stock

47.5

44.0

43.2

38.7

35.8

    Additional Paid in Capital

180.7

167.3

133.0

60.6

56.0

    Gain on Capital Reduction

5.3

4.9

4.9

4.8

4.5

    Gains on Disposal of Treasury Stock

11.1

10.2

10.4

10.1

1.1

    Other Capital Surplus

4.6

4.2

4.3

12.7

6.3

    Consideration for Conversion Rights

-

-

0.7

-

-

    Consideration for Stock Warrants

-

-

2.6

-

-

    Retained Earnings

361.0

302.3

274.8

-

-

    Treasury Stock

-0.5

-0.5

-0.5

-0.5

-3.7

    Legal Reserve

-

-

-

2.5

1.6

    Voluntary Reserve

-

-

-

105.6

66.7

    Unappropriated Retained Earnings

-

-

-

71.4

40.8

    Gain/Losses on Valuation of Securities A

21.0

4.5

3.8

1.8

4.4

    Gain/Losses on Valt of Derivatives

-

0.1

-0.1

-

-

    Loss-Valuation of Currency Swaps

-

-

-

-0.3

-1.3

    Capital Change, Equity Method

-0.2

0.0

-

0.6

-

    Overseas Bus. Translation Debit/Credit

-0.4

-0.3

0.0

-

-

    Adj. for Capital Surplus

0.0

0.0

0.0

-

-

    Adj.-Accum. Other Comprehensive Income

0.0

0.0

0.0

-

-

Total Equity

630.0

536.6

477.0

308.1

212.1

 

 

 

 

 

 

Total Liabilities & Shareholders' Equity

895.0

746.8

677.4

612.3

436.2

 

 

 

 

 

 

    S/O-Ordinary Shares

10.8

10.8

10.4

9.7

9.6

Total Common Shares Outstanding

10.8

10.8

10.4

9.7

9.6

T/S-Ordinary Shares

0.0

0.0

0.0

0.0

0.2

Accumulated Intangible Amort, Suppl.

9.2

6.8

5.4

-

-

Deferred Revenue - Long Term

7.0

6.9

-

-

-

Deferred Revenue, Current

3.1

1.7

1.7

43.9

2.1

Full-Time Employees

1,457

1,335

1,374

1,341

1,285

Number of Common Shareholders

-

-

14,390

23,102

2,171

Current maturities

-

-

0.2

38.8

11.9

Long Term Debt Maturing in Year 3

-

10.0

3.8

-

-

Total Long Term Debt, Supplemental

-

10.0

4.0

38.8

11.9

 

 

Annual Cash Flows

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

12 Months

12 Months

12 Months

12 Months

12 Months

UpdateType/Date

Updated Normal
31-Dec-2012

Updated Normal
31-Dec-2011

Restated Normal
31-Dec-2011

Updated Normal
31-Dec-2009

Updated Normal
31-Dec-2008

Filed Currency

KRW

KRW

KRW

KRW

KRW

Exchange Rate (Period Average)

1126.848795

1107.891393

1156.281981

1276.385219

1100.562842

Auditor

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

KPMG LLP

Auditor Opinion

Unqualified with Explanation

Unqualified with Explanation

Unqualified with Explanation

Unqualified

Unqualified

 

 

 

 

 

 

Net Income or Loss

49.4

52.0

98.6

63.1

44.4

    Depreciation

12.1

10.1

7.8

11.4

8.3

    Amort. of Intangibless

1.8

1.7

1.6

1.8

1.2

    L-Equity Method Valuation

-

-

-

1.5

0.1

    Loss on Invesment in Affiliates

2.9

0.7

1.9

-

-

    Payment for Retirement Allow., ONCI

8.8

7.1

6.0

4.1

6.3

    Amort-Bad Debt Exp

-

-

-

-

0.5

    Amort-Discount on Bond with Warrant

-

-

-

0.0

-

    Amort-Convertible Right Adjustment

-

-

-

0.3

-

    Amort-Discount on Convertible Bond Issue

-

-

-

0.0

-

    Amort-Subscription Warrant Adjustment

-

-

-

0.3

-

    Loss-Disposal of Trade Receivable

-

-

-

0.0

-

    Loss-Reduction of Intangible Assets

-

-

-

2.5

-

    Rec. of Losses on Valt of Inventories

-0.2

-

-

-

-

    Loss-Scraping of Inventory

-

-

-

0.8

-

    Loss-Valuation of Inventory

-

-

-

0.5

0.1

    L-Reduction Secs for Sale

-

-

-

0.5

0.3

    Loss on Disposal of Investment Propertie

-

-

0.6

1.4

-

    Loss on Disposal of Property, Plant and

0.3

0.4

0.0

0.1

0.0

    Loss on Disposal of Intangible Assets

0.0

-

0.1

-

-

    Impmt Loss on Tangibles

-

0.0

-

-

-

    Loss on Disposal of Financial Assets Ava

-

-

0.0

-

-

    Loss on Valt of Derivative Fincl Assets

-

-

0.3

-

-

    Losses on Foreign Currency Translation

0.5

0.4

0.6

0.1

15.6

    Expenses of Allow. for Other DA

0.0

-

0.2

0.2

0.0

    Expense of Allow. for DA

0.1

0.2

-

-

-

    L-Currency Swap Valuation

-

-

-

3.5

-

    Loss-Currency Swap Transaction

-

-

-

0.8

0.1

    Loss on Derivatives Transaction

-

0.1

0.5

-

-

    Miscellaneous Loss(1)

-

-

-

0.0

0.0

    Rec. of Allow. for DA

-

-

-0.4

0.0

-0.1

    Gain-Valuation of Currency Swap

-

-

-

-

-15.0

    Gain-Currency Swap Transaction

-

-

-

-

-0.1

    Loss on Redemption of Bonds

-

1.3

-

-

-

    Interest Expenses

1.9

3.1

4.9

-

-

    Gains on Foreign Currency Translation

-0.6

-0.3

-1.2

-4.7

-0.9

    G-Inv.Asset Disp

-

-

-

-4.6

-7.0

    Gain on Disposal of Property, Plant and

-0.1

-0.1

0.0

-0.1

-0.1

    Gain on Disposal of Intangible Assets

-

0.0

-

-

-

    Gain on Disposal of Financial Assets Ava

-0.6

-

-0.2

-

-

    Gains on Valts of Derivatives Assets

-

0.0

-

-

-

    Gain on Derivatives Transaction

-0.1

0.0

-

-

-

    Gain under Equity Method

-0.2

-

-

-0.5

-0.5

    Dividend Income

-0.4

-0.1

-0.1

-

-

    Interest Income

-0.7

-2.8

-1.3

-

-

    Corporate Taxes Expense

15.5

25.7

27.8

-

-

    Trade Receivables

0.1

-57.1

21.2

-5.9

-35.6

    Account Receivables

-0.1

0.1

0.2

-0.4

1.2

    Accrued Income

-

-

-

-0.1

0.0

    Advance Payments

1.9

-1.3

-0.5

0.1

-0.1

    Prepaid Expenses

0.1

-0.4

0.2

0.5

-0.8

    Inventory

-11.0

-2.4

22.2

-79.1

-27.4

    Deferred TAx-Assets

-

-

-

-1.0

-0.5

    Currency Swap

-

-

-

-0.1

0.0

    Deferred Tax, Liabilities

-

-

-

2.2

-0.6

    Trade Payable

-12.0

31.1

-39.1

41.4

9.8

    Other Payable

0.7

7.0

3.7

-5.9

-18.2

    LT Account Payables

-0.2

-

-

-

-

    Accrued Income TAx

-

-

-

14.3

-4.8

    Accrued Expenses

1.5

-2.2

0.9

3.3

3.3

    Accrued Dividends

-

-

-

0.0

0.0

    Advance from Customers

0.0

0.1

-42.5

38.0

1.1

    Withholdings

-0.1

0.0

-0.1

2.6

2.2

    R&D Withholdings

0.2

2.3

-

-

-

    Value Added Taxes Withholdings

-1.7

0.6

-0.5

0.3

1.8

    Guarantee Deposit Withholdings

-0.1

0.2

-0.1

-

-

    Payment of Plan Assets

-6.4

-

-

-

-

    Estimated Liabilities for Returned Goods

1.3

-0.6

1.5

-

1.5

    Payment for Retirement Allow.

-1.1

-1.5

-3.9

-4.2

-2.0

    Prov. for Fixed Benefit Liabilities

0.1

0.4

0.1

-

-

    Plan Assets

-

-4.8

-3.9

-

-

    Currency Swap Liability

-

-

-

-0.2

-

    Succession to Prov. for Retm&Sevr Benf

-

-

-

0.0

-0.2

    Unearned Income

0.7

7.1

-

-

-

    Prov.for Lawsuit

-

-0.5

0.7

-

-

    Retire Insur Dep.

-

-

-

-1.2

-2.6

    National Pension

-

-

-

0.0

0.0

    Overseas Business Translation Debit

-0.2

-0.3

0.0

-

-

    Miscellaneous Gain

-

-0.2

-0.6

-

-

    Cash-Interest Received

0.8

2.7

0.8

-

-

    Cash-Interest Paid

-1.9

-1.6

-2.4

-

-

    Cash-Dividend Income

0.4

0.4

0.4

-

-

    Cash-Tax Paid

-18.2

-28.8

-32.5

-

-

    Adj.

0.0

0.0

0.0

-

-

Cash from Operating Activities

45.0

49.5

73.5

87.8

-18.8

 

 

 

 

 

 

    Decr-ST Finl Assets

44.9

113.8

37.6

0.1

6.0

    Disp of Market Secs.

-

-

-

5.5

13.0

    Disposal of Securities Available-for-Sal

1.1

-

1.0

-

-

    Decrease in Guarantee Deposit

0.1

0.0

-

1.3

0.0

    Disposal of Investment Properties

-

-

0.5

-

-

    Decrease-Intangible Assets

0.0

0.0

2.0

-

-

    Disp-Machinery

-

-

-

0.2

1.2

    Disposal Trans Equip

-

-

-

0.0

0.1

    Disp Tools/Supplies

-

-

-

-

0.0

    Decrease-Development Cost

-

-

-

-

0.1

    Disposal-Construction in Progress

-

-

-

0.0

-

    Disposal of Property, Plant and Equipmen

0.7

1.8

0.3

-

-

    Purchase of Current Financial Instrument

-3.8

-67.2

-85.6

-34.0

-

    Increase in Current Loans

-

-

-0.1

-

-

    Purchase of Non-Current Fincl Instrm

-0.5

0.0

-

-1.8

-0.5

    Inc-Investment Secs

-

-

-

-0.1

-0.5

    Purchase of Sec. Available-for-Sale

-42.7

-31.7

-2.5

-

-

    Purchase of Invmt in Affiliates

-13.5

-1.2

-0.1

-

-

    Increase in Guarantee Deposit

-1.2

-0.7

-0.1

-1.3

-1.0

    Purchase of Buildings

-

-

-

-3.6

-

    Purchase of Structures

-

-

-

0.0

0.0

    Purchase of Machinery

-

-

-

-5.2

-1.7

    Purchase of Vehicles

-

-

-

-0.3

-0.4

    Acq. in Tools/Suppl.

-

-

-

-0.9

-0.8

    Purchase of Construction in Progress

-

-

-

-1.9

-49.1

    Purchase of Tangibles

-57.9

-39.3

-24.8

-

-

    Purchase of Industrial Property Rights

-

-

-

-0.1

-2.3

    Purchase of Development Costs

-

-

-

-2.0

-3.4

    Purchase of Other Intangibless

-

-

-

-1.4

0.0

    Purchase of Equity Method Sec.

-

-

-

-9.9

-5.7

    Purchase of Intangibless

-7.3

-10.4

-1.8

-

-

    Purchase of Subsidiaries

-

-

-1.5

-

-

Cash from Investing Activities

-80.2

-34.9

-75.1

-55.6

-45.0

 

 

 

 

 

 

    Increase in Current Borrowings

73.0

31.7

7.8

5.5

58.7

    Incr-Security Deposits

-

-

-

0.1

0.0

    Issuance-Bond with Warrant

-

-

-

23.4

-

    Dec-Lease Guarantee

-

-

-

-

0.1

    Proceeds from Sale of Treasury Stock

-

-

-

11.4

0.2

    Increase in Non-Current Borrowings

0.5

9.4

-

-

27.3

    Increase-Convertible Bond

-

-

-

23.4

-

    Decrease in Current Borrowings

-33.5

-41.6

-43.5

-65.5

-

    Repay Curr LT Liabs

-

-

-

-11.8

-9.1

    Dec in Sec Deposit

-

-

-

-

-0.1

    Decrease in Rental Guarantee Deposit

-0.1

0.0

-0.3

0.0

0.0

    Decrease in Non-Current Borrowings

-

-

-1.6

-3.5

-

    Decrease in Bonds with Warrant

-

-28.0

-

-

-

    Dividend Paid

-13.7

-15.7

-9.9

-6.9

-8.0

    Decrease in Derivatives(1)

0.7

1.1

6.6

-

-

    Increase in Invmt in Subsidiaries

-0.3

1.8

-5.6

-

-

    Exercise of Stock Warrants

-

27.1

-

-

-

    Rights Issue

-

0.5

54.6

-

-

Cash from Financing Activities

26.6

-13.9

8.0

-23.9

69.1

 

 

 

 

 

 

Foreign Exchange Effects

0.0

0.0

-0.1

-

-

Incs or Decs in Cash & Cash Equivalents

-8.5

0.8

6.3

8.3

5.2

 

 

 

 

 

 

Cash and Cash Equivalents at Beginning

28.6

28.3

20.9

9.1

5.3

Cash and Cash Equivalents at End

20.1

29.1

27.1

17.4

10.5

    Cash Interest Paid

1.9

1.6

2.4

-

-

    Cash Taxes Paid

18.2

28.8

32.5

-

-

 

 

Financial Health

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 

 

Key Indicators USD (mil)

 

Quarter
Ending
30-Jun-2013

Quarter
Ending
Yr Ago

Annual
Year End
31-Dec-2012

1 Year
Growth

3 Year
Growth

5 Year
Growth

Total Revenue1 (?)

184.0

1.55%

720.4

5.71%

8.07%

12.91%

Research & Development1 (?)

-

-

63.0

17.94%

16.53%

21.17%

Operating Income1 (?)

15.2

8.70%

66.0

-12.92%

-14.60%

4.93%

Income Available to Common Excl Extraord Items1 (?)

14.1

38.85%

47.6

-3.11%

-12.66%

3.87%

Basic EPS Excl Extraord Items1 (?)

1.27

35.55%

4.41

-4.31%

-15.79%

1.34%

Capital Expenditures2 (?)

45.8

239.26%

65.2

33.49%

55.09%

-0.27%

Cash from Operating Activities2 (?)

12.0

217.15%

45.0

-7.47%

-23.19%

7.58%

Free Cash Flow (?)

-32.5

-

-21.3

-

-

-

Total Assets3 (?)

936.1

24.54%

895.0

10.93%

10.21%

17.53%

Total Liabilities3 (?)

240.3

15.46%

265.0

16.66%

-7.26%

8.30%

Total Long Term Debt3 (?)

7.3

-7.43%

7.6

-12.32%

-52.10%

-28.98%

Employees3 (?)

-

-

1457

9.14%

2.80%

4.04%

Total Common Shares Outstanding3 (?)

11.7

8.01%

10.8

0.00%

3.46%

2.41%

1-ExchangeRate: KRW to USD Average for Period

1122.022568

 

1126.848795

 

 

 

2-ExchangeRate: KRW to USD Average for Period

1103.219597

 

1126.848795

 

 

 

3-ExchangeRate: KRW to USD Period End Date

1147.202838

 

1066.400024

 

 

 

Key Ratios

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Profitability

Gross Margin (?)

31.24%

33.71%

40.60%

41.94%

39.57%

Operating Margin (?)

9.16%

11.12%

19.21%

18.56%

13.16%

Pretax Margin (?)

9.01%

11.21%

18.42%

16.27%

11.47%

Net Profit Margin (?)

6.61%

7.21%

14.34%

12.52%

9.47%

Financial Strength

Current Ratio (?)

2.06

2.66

2.49

1.72

1.56

Long Term Debt/Equity (?)

0.01

0.02

0.01

0.21

0.29

Total Debt/Equity (?)

0.12

0.06

0.14

0.35

0.66

Interest Coverage (?)

-

186,709.83

-

-

-

Management Effectiveness

Return on Assets (?)

6.13%

7.07%

15.38%

12.76%

10.03%

Return on Equity (?)

8.32%

9.55%

25.26%

25.73%

19.43%

Efficiency

Receivables Turnover (?)

3.70

4.08

4.87

3.90

3.63

Inventory Turnover (?)

2.70

2.55

2.29

2.28

3.13

Asset Turnover (?)

0.89

0.94

1.07

1.02

1.06

Market Valuation USD (mil)

P/E (TTM) (?)

24.46

.

Enterprise Value2 (?)

1,382.5

Price/Sales (TTM) (?)

1.97

.

Enterprise Value/Revenue (TTM) (?)

1.93

Price/Book (MRQ) (?)

2.02

.

Enterprise Value/EBITDA (TTM) (?)

17.86

Market Cap as of 27-Sep-20131 (?)

1,498.5

.

 

 

1-ExchangeRate: KRW to USD on 27-Sep-2013

1076.247633

 

 

 

2-ExchangeRate: KRW to USD on 30-Jun-2013

1147.202838

 

 

 

 

 

Annual Ratios

 

Financials in: USD (mil)

 

Except for share items (millions) and per share items (actual units)

 



 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Financial Strength

Current Ratio (?)

2.06

2.66

2.49

1.72

1.56

Quick/Acid Test Ratio (?)

1.11

1.60

1.47

0.87

0.89

Working Capital1 (?)

222.7

275.5

259.9

165.6

87.0

Long Term Debt/Equity (?)

0.01

0.02

0.01

0.21

0.29

Total Debt/Equity (?)

0.12

0.06

0.14

0.35

0.66

Long Term Debt/Total Capital (?)

0.01

0.01

0.01

0.15

0.17

Total Debt/Total Capital (?)

0.11

0.06

0.12

0.26

0.40

Interest Coverage (?)

-

186,709.83

-

-

-

Payout Ratio (?)

23.56%

27.06%

14.53%

13.86%

18.10%

Effective Tax Rate (?)

23.93%

33.07%

21.97%

23.06%

17.44%

Total Capital1 (?)

707.0

569.3

544.0

415.5

351.4

 

 

 

 

 

 

Efficiency

Asset Turnover (?)

0.89

0.94

1.07

1.02

1.06

Inventory Turnover (?)

2.70

2.55

2.29

2.28

3.13

Days In Inventory (?)

135.42

143.19

159.30

160.36

116.44

Receivables Turnover (?)

3.70

4.08

4.87

3.90

3.63

Days Receivables Outstanding (?)

98.53

89.37

74.90

93.61

100.56

Revenue/Employee2 (?)

522,463

499,318

508,576

411,901

318,869

Operating Income/Employee2 (?)

47,856

55,521

97,693

76,455

41,971

EBITDA/Employee2 (?)

57,935

63,996

104,671

87,178

48,410

 

 

 

 

 

 

Profitability

Gross Margin (?)

31.24%

33.71%

40.60%

41.94%

39.57%

Operating Margin (?)

9.16%

11.12%

19.21%

18.56%

13.16%

EBITDA Margin (?)

11.09%

12.82%

20.58%

21.16%

15.18%

EBIT Margin (?)

9.16%

11.12%

19.21%

18.56%

13.16%

Pretax Margin (?)

9.01%

11.21%

18.42%

16.27%

11.47%

Net Profit Margin (?)

6.61%

7.21%

14.34%

12.52%

9.47%

R&D Expense/Revenue (?)

8.74%

7.83%

6.99%

6.97%

6.67%

COGS/Revenue (?)

68.76%

66.29%

59.40%

58.06%

60.43%

SG&A Expense/Revenue (?)

12.95%

14.36%

13.59%

15.62%

18.77%

 

 

 

 

 

 

Management Effectiveness

Return on Assets (?)

6.13%

7.07%

15.38%

12.76%

10.03%

Return on Equity (?)

8.32%

9.55%

25.26%

25.73%

19.43%

 

 

 

 

 

 

Valuation

Free Cash Flow/Share2 (?)

-1.97

-0.01

4.57

8.13

-6.97

Operating Cash Flow/Share 2 (?)

4.41

4.41

7.17

9.87

-1.72

1-ExchangeRate: KRW to USD Period End Date

1066.400024

1152

1134.9

1164.475

1259.55

2-ExchangeRate: KRW to USD Average for Period

1066.400024

1152

1134.9

1164.475

1259.55

 

Current Market Multiples

Market Cap/Earnings (TTM) (?)

24.51

Market Cap/Equity (MRQ) (?)

2.02

Market Cap/Revenue (TTM) (?)

1.97

Market Cap/EBIT (TTM) (?)

24.37

Market Cap/EBITDA (TTM) (?)

18.17

Enterprise Value/Earnings (TTM) (?)

24.10

Enterprise Value/Equity (MRQ) (?)

1.99

Enterprise Value/Revenue (TTM) (?)

1.93

Enterprise Value/EBIT (TTM) (?)

23.96

Enterprise Value/EBITDA (TTM) (?)

17.86


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.14

UK Pound

1

Rs.99.02

Euro

1

Rs.83.87

 

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.